Guest Post: Examining the Recently Announced Compulsory Licenses on anticancer drugs
In light of the recent decision to issue compulsory licenses for three anti-cancer drugs, Madhulika Vishwanathan brings us her third submission for our SpicyIP Fellowship application. After looking into the possible legal provisions that could have been used in pursuing this decision, she examines how generics may follow up on this decision by noting the differences in approach that they will have to take regarding small molecule drugs and biologics. (Note: Much of the first half includes quoted provisions, so […]
Guest Post: Examining the Recently Announced Compulsory Licenses on anticancer drugs Read More »